Teva Pharmaceuticals (NYSE:TEVA) announced the U.S. launch of the first generic version of the twice-daily Perforomist inhalation solution.
Parsippany, N.J.-based Teva Pharmaceuticals — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries Ltd. — launched the formoterol fumarate inhalation solution (20 mcg/2 mL) with an indication for treating bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
According to a Teva news release, Perforomist has annual sales totaling more than $299 million in the U.S., per IQVIA data as of March 2021.
“Teva is pleased to provide patients with first-to-market access to a generic version of Perforomist (formoterol fumarate inhalation solution),” Teva USA SVP & COO of U.S. generics Christine Baeder said in the release.
